Epizyme, Inc. has terminated its study of tazemetostat with enzalutamide or abiraterone/​prednisone in participants with advanced prostate cancer (CELLO-1) due to a sponsor decision unrelated to safety concerns.
1 Discontinued Research Program
Epizyme, Inc. has terminated its study of tazemetostat with enzalutamide or abiraterone/​prednisone in participants with advanced prostate cancer (CELLO-1) due to a sponsor decision unrelated to safety concerns.
1 Discontinued Research Program
